AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates

Financial Performance - AquaBounty Technologies reported a quarterly loss of $0.88 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.89, and an improvement from a loss of $1.60 per share a year ago [1] - The company posted revenues of $0.05 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 52%, and down from $0.73 million in the same quarter last year [2] - Over the last four quarters, AquaBounty has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - AquaBounty Technologies shares have declined approximately 60% since the beginning of the year, contrasting with the S&P 500's gain of 19.8% [3] - The current Zacks Rank for AquaBounty is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.61 on revenues of $0.1 million, and for the current fiscal year, it is -$4.86 on revenues of $0.75 million [7] - The estimate revisions trend for AquaBounty is mixed, and future earnings expectations will depend on management's commentary during the earnings call [3][4] Industry Context - AquaBounty Technologies operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 38% of over 250 Zacks industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact AquaBounty's stock [5][8]